Home › Targets › CD3
CD3 (7 companies · 37 programs)
Companies with an active program directed at CD3.
- XmAb819 — Clear Cell Renal Cell Carcinoma Phase 1
- XmAb819 — Colorectal Cancer Phase 1
- XmAb819 — Non-Small Cell Lung Cancer Phase 1
- XmAb541 — Ovarian Cancer Phase 1
- plamotamab — Rheumatoid Arthritis Phase 1
- XmAb657 — Idiopathic Inflammatory Myopathies Phase 1
- xaluritamig — Metastatic Castration-Resistant Prostate Cancer Phase 3
- ASP2138 — Gastric Cancer Phase 1
- ASP2138 — Gastroesophageal Junction Cancer Phase 1
- ASP2138 — Pancreatic Cancer Phase 1
- CLN-978 — Systemic Lupus Erythematosus Phase 1
- CLN-978 — Rheumatoid Arthritis Phase 1
- CLN-978 — Sjögren's Disease Phase 1
- velinotamig — Systemic Lupus Erythematosus Phase 1
- CLN-049 — Acute Myeloid Leukemia Phase 1
- CLN-049 — Myelodysplastic Syndrome Phase 1
- CLN-978 — Lupus Nephritis Phase 2
- velinotamig — Immune Thrombocytopenia Phase 1
- velinotamig — Autoimmune Hemolytic Anemia Phase 1
- VIR-5500 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- VIR-5818 — Breast Cancer Phase 1
- VIR-5818 — Colorectal Cancer Phase 1
- VIR-5525 — Non-Small Cell Lung Cancer Phase 1
- VIR-5525 — Colorectal Cancer Phase 1
- VIR-5525 — Head and Neck Squamous Cell Carcinoma Phase 1
- VIR-5525 — Cutaneous Squamous Cell Carcinoma Phase 1
- VIR-5500 — Metastatic Hormone-Sensitive Prostate Cancer Phase 1
- mipletamig — Acute Myeloid Leukemia Phase 1
- APVO442 — Prostate Cancer Preclinical
- APVO455 Preclinical
- APVO451 Preclinical
- APVO452 — Prostate Cancer Preclinical
- ADG138 Preclinical
- ADG152 Preclinical
- JANX007 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- JANX011 Phase 1
